To hear about similar clinical trials, please enter your email below
Trial Title:
A Retrospective Study Reveals the Relationship Between gp42-IgG Epitopes and EBV-associated NPC
NCT ID:
NCT05949749
Condition:
Nasopharyngeal Carcinoma
Conditions: Official terms:
Nasopharyngeal Carcinoma
Study type:
Observational
Overall status:
Recruiting
Study design:
Time perspective:
Cross-Sectional
Intervention:
Intervention type:
Diagnostic Test
Intervention name:
Epitope exploration
Description:
Explore the epitope landscape of gp42-IgG of cases in comparison with that of controls.
Arm group label:
Case
Arm group label:
Control
Summary:
Epstein-barr virus (EBV) infection is a necessary factor of nasopharyngeal carcinoma
(NPC). The incidence of NPC in endemic regions reaches 24.60/100,000 people, far higher
than that of the worldwide average. However, no EBV prophylactic vaccines is clinically
available so far, which is largely hampered by the difficulties in selecting optimal
vaccine design target out of 13 glycoproteins on the surface of EBV. In this study, we
utilized humanized gp42-IgG antibodies to explore the dominant epitopes of gp42, one of
the functional EBV glycoproteins during virus entry, to facilitate prophylactic vaccine
design.
Criteria for eligibility:
Study pop:
Chinese.
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
- Controls underwent physical examinations or primary NPC cases confirmed by pathology
or cytology.
- If cases, at stage I-IVB diagnosed by radiology according to AJCC/UICC 8th.
- If cases, Karnofsky score (KFS)≥70, estimated survival span>12 months.
- If cases, no disordered of major organs is found; blood test, liver, and kidney
functions are basically normal.
- If cases, at least one measurable lesion according to Response Evaluation Criteria
in Solid Tumours (RECIST) 1.1.
Exclusion Criteria:
- History of other malignant diseases.
- History of severe systemic diseases or heart, lung, liver, or kidney disfunction.
- History of severe neurological, metal, endocrine diseases.
- History of HBV, HCV, HIV, TP, or TB infection.
- If controls, physical examination reveals systemic diseases including malignant
diseases.
- If cases, incomplete blood and pathological sample data.
- If cases, not receiving primary treatment in this facility.
- Other individuals investigators find not suitable for the trial.
Gender:
All
Minimum age:
N/A
Maximum age:
N/A
Healthy volunteers:
Accepts Healthy Volunteers
Locations:
Facility:
Name:
Sun Yat-sen Memorial Hospital
Address:
City:
Guangzhou
Zip:
510000
Country:
China
Status:
Recruiting
Contact:
Last name:
Xiang-Wei Kong, Ph.D.
Start date:
August 25, 2023
Completion date:
September 30, 2024
Lead sponsor:
Agency:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Agency class:
Other
Source:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05949749
